Latest News & Features
Americas
Medical cannabis company Medterra and has hit back at claims it misappropriated trade secrets at a federal court in Florida, holding that the company alleging the IP violation had failed to produce sufficient evidence. 14 January 2021
Big Pharma
Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz. 14 January 2021
Americas
Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid. 14 January 2021
article
With the pharmaceutical and biotechnology industry constantly evolving, new and complex therapies are being introduced which challenge the current limitations within patentability. In order for these new innovations to be well protected the patenting process must evolve too. 14 January 2021
Americas
Two federal agencies in the US have agreed to share confidential business information about the manufacture of chemicals that are produced and imported, in efforts to improve the protection of workers who may be exposed to a new chemical substance. 14 January 2021
Americas
Illumina tried to secure its control over the DNA sequencing technology market by violating antitrust law, according to a suit by BGI Americas and two of its subsidiaries, at the US Court for the District Court of San Francisco. 12 January 2021
Big Pharma
Sanofi will buy British immunotherapy firm Kymab for up to $1.45 billion, as it seeks to expand in the rapidly growing immunotherapy field. 12 January 2021
Americas
The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid. 11 January 2021
Americas
Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible. 8 January 2021
Americas
Generic drug makers are trying to persuade the US Supreme Court to retain an administrative process for challenging patents, in the latest bid to discredit the controversial decision handed down in Arthrex v Smith & Nephew. 7 January 2021